Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on off-the-shelf T-cell receptor immunotherapies targeting infectious diseases and oncology. The company entered the public markets through a SPAC merger and filed its 10-Q with the SEC in August 2022, marking an early period of its life as a reporting company in the biotechnology sector. Tevogen Bio's pipeline centers on allogeneic cytotoxic T lymphocyte programs designed to address viral pathogens and solid tumors. Its current status reflects ongoing clinical development activity within the broader cell-therapy landscape. Sign up on SpacDesk for full filing history, sponsor data, and real-time analytics on TVGN and hundreds of other SPAC transactions.